Table 2.
Features of the participants, shown as mean ± SEM or number of participants (%). Groups are not significantly different.
| Feature | N = 562 |
|---|---|
| Age (years) | 44.1 ± 0.7 |
| Age < 18 years | 65 (11.6) |
| Age > 18 years | 497 (88.4) |
| Asthma duration (years) | 28.5 ± 0.7 |
| Male | 202 (35.9) |
| Hispanic ethnicity | 24 (4.3) |
| Race | |
| White | 350 (62.3) |
| Black | 142 (25.3) |
| More than one race | 49 (8.7) |
| Other | 21 (3.7) |
| Severe asthma (modified dichotomous ERS/ATS definition) | 328 (58.4) |
| Highest household educational attainment | |
| Did not complete high school | 10 (1.8) |
| High school diploma | 57 (10.1) |
| Some college or technical training | 115 (20.5) |
| Associate degree | 87 (15.5) |
| Bachelor’s degree | 289 (51.4) |
| Decline to answer | 4 (0.7) |
| Highest annual household income | |
| Less than $25,000 | 104 (18.5) |
| $25,000 to $49,999 | 114 (20.3) |
| $50,000 to $99,999 | 159 (28.3) |
| $100,000 or more | 109 (19.4) |
| Decline to answer | 76 (13.5) |
| Saw an asthma specialist (previous year)1 | 306 (54.4) |
| Asthma healthcare utilization (previous year) | |
| Unscheduled physician visit | 250 (44.5) |
| Emergency department | 143 (25.4) |
| Hospitalization | 70 (12.5) |
| Intubation for asthma (ever in lifetime) | 35 (6.2) |
| Daily asthma medications | |
| Inhaled corticosteroid | 489 (87.0) |
| Long-acting beta-agonist | 439 (78.1) |
| Long-acting anti-muscarinic | 52 (9.3) |
| Leukotriene receptor antagonist | 226 (40.2) |
| Theophylline | 23 (4.1) |
| Systemic corticosteroids | 91 (16.2) |
| Biologic | 43 (7.7) |
| Asthma Control Test Score | 17.2 ± 0.2 |
| 23-25 | 66 (11.8) |
| 20-22 | 153 (27.3) |
| 17-19 | 116 (20.7) |
| 14-16 | 98 (17.5) |
| 11-13 | 65 (11.6) |
| 8-10 | 42 (7.5) |
| 5-7 | 20 (3.6) |
| Baseline lung function (% predicted value) | |
| FVC | 86.7 ± 0.8 |
| FEV1 | 74.2 ± 0.9 |
1
Severe asthma (modified dichotomous ERS/ATS definition), n = 236 (72.0%), non-severe asthma, n = 70 (29.9%)